Abstract:Science Progress, Volume 107, Issue 2, April-June 2024. Idiopathic pulmonary fibrosis is a chronic and progressive interstitial lung disease with a poor prognosis. Idiopathic pulmonary fibrosis is characterized by repeated alveolar epithelial damage leading to abnormal repair. The intercellular microenvironment is disturbed, leading to continuous activation of fibroblasts and myofibroblasts, deposition of extracellular matrix, and ultimately fibrosis. Moreover, pulmonary fibrosis was also found as a COVID-19 complication. Currently, two drugs, pirfenidone and nintedanib, are approved for clinical therapy worldwide. However, they can merely slow the disease's progression rather than rescue it. These two drugs have other limitations, such as lack of efficacy, adverse effects, and poor pharmacokinetics. Consequently, a growing number of molecular therapies have been actively developed. Treatment options for IPF are becoming increasingly available. This article reviews the research platform, including cell and animal models involved in molecular therapy studies of idiopathic pulmonary fibrosis as well as the promising therapeutic targets and their development progress during clinical trials. The former includes patient case/control studies, cell models, and animal models. The latter includes transforming growth factor-beta, vascular endothelial growth factor, platelet-derived growth factor, fibroblast growth factor, lysophosphatidic acid, interleukin-13, Rho-associated coiled-coil forming protein kinase family, and Janus kinases/signal transducers and activators of transcription pathway. We mainly focused on the therapeutic targets that have not only entered clinical trials but were publicly published with their clinical outcomes. Moreover, this work provides an outlook on some promising targets for further validation of their possibilities to cure the disease.

Drug therapy of idiopathic pulmonary fibrosis

Idiopathic Pulmonary Fibrosis: 8 Years On After Nintedanib and Pirfenidone Approval—What Is on the Horizon?

Current and novel drug therapies for idiopathic pulmonary fibrosis

An up-to-date review of approved and emerging antibody therapies for idiopathic pulmonary fibrosis

Updates in pharmacotherapy for idiopathic pulmonary fibrosis

Progress in treatment for idiopathic pulmonary fibrosis

Perspectives of PDE Inhibitor on Treating Idiopathic Pulmonary Fibrosis

Novel drug targets for idiopathic pulmonary fibrosis

Targeting Growth Factor and Cytokine Pathways to Treat Idiopathic Pulmonary Fibrosis

Progress on treatment of idiopathic pulmonary fibrosis

Comprehensive review of potential drugs with anti-pulmonary fibrosis properties

Emerging Opportunities to Treat Idiopathic Pulmonary Fibrosis: Design, Discovery, and Optimizations of Small-Molecule Drugs Targeting Fibrogenic Pathways.

Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis

Progress in understanding and treating idiopathic pulmonary fibrosis: recent insights and emerging therapies

[Idiopathic pulmonary fibrosis: recent diagnostic and therapeutic advances]

Research Progress in the Molecular Mechanisms, Therapeutic Targets, and Drug Development of Idiopathic Pulmonary Fibrosis

Research progress of idiopathic pulmonary fibrosis and its treatment

Novel therapeutic strategies and drugs for idiopathic pulmonary fibrosis

Exploring therapeutic targets for molecular therapy of idiopathic pulmonary fibrosis

Treatment of idiopathic pulmonary fibrosis: an update on emerging drugs in phase II & III clinical trials

Advances of Targets and Therapeutic Drugs for Idiopathic Pulmonary Fibrosis